TITLE

Gut, inflammation and osteoporosis: basic and clinical concepts

AUTHOR(S)
Tilg, H.; Moschen, A. R.; Kaser, A.; Pines, A.; Dotan, I.
PUB. DATE
May 2008
SOURCE
Gut;May2008, Vol. 57 Issue 5, p684
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic inflammatory disorders such as inflammatory bowel diseases (IBD) affect bone metabolism and are frequently associated with the presence of osteoporosis. Bone loss is regulated by various mediators of the immune system such as the pro-inflammatory cytokines tumour necrosis factor-α (TNF-α), interleukin-1 β (IL-1 β), IL-6, or interferon-gamma. TNF-α, a master cytokine in human IBD, causes bone erosions in experimental models and these effects are exerted by osteoclasts. Other TNF-related cytokines such as receptor activator of nuclear factor kappa B (RANK), its ligand, RANKL, and osteoprotegerin are important mediators in inflammatory processes in the gut and are critically involved in the pathophysiology of bone loss. The awareness and early diagnosis of osteoporosis in states of chronic inflammation, together with applied therapies such as bisphosphonates, may be beneficial in inflammation-associated osteoporosis. Although several mechanisms may contribute to osteoporosis in patients with IBD and coeliac disease, inflammation as an important factor has so far been neglected. As key inflammatory mediators in IBD such as TNF-α are involved in the disease process both in gut and bone, we hypothesise that neutralisation of TNF-α could prove an efficient strategy in the treatment of inflammation-related osteoporosis in the future.
ACCESSION #
31931748

 

Related Articles

  • Therapie chronisch-entzündlicher Darmerkrankungen. Mecklenburg, Ingo // Praxis (16618157);2/12/2014, Vol. 103 Issue 4, p203 

    Inflammatory Bowel Disease (i.e. Crohn's Disease and Ulcerative Colitis) show a rising incidence throughout Switzerland. An early and individualized therapy usually enables the effective treatment of both diseases and prevents structural gastrointestinal damage or surgical interventions. The...

  • Natalizumab.  // Reactions Weekly;6/25/2005, Issue 1057, p14 

    Discusses research being done on progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. Reference to a study by G. Van Assche et al published in the 2005 issue of the "New England Journal of Medicine"; Findings of the study.

  • Clinical epidemiology -- how important now? Binder, V // Gut;May2005, Vol. 54 Issue 5, p574 

    The article focuses on the putative risk of haematopoietic cancer in relation to modern strong immunosuppressive treatment in inflammatory bowel disease. The natural history of a chronic disease should ideally be the background for any therapeutic trial. Modern information technology has...

  • Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases. Kawaguchi, Kiichiro; Matsumoto, Tsukasa; Kumazawa, Yoshio // Current Topics in Medicinal Chemistry;Jul2011, Vol. 11 Issue 14, p1767 

    Oxidative stress and inflammatory responses sustained for a long period of time cause many diseases. A proinflammatory cytokine, tumor necrosis factor a (TNF-a), plays a pivotal role in the pathogenesis of chronic and autoimmune diseases. The present review, supplemented by hitherto unpublished...

  • A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. Feagan, Brian G.; Fedorak, Richard N.; Irvine, E. Jan; Wild, Gary; Sutherland, Lloyd; Steinhart, A. Hillary; Greenberg, Gordon R.; Koval, John; Wong, Cindy J.; Hopkins, Marybeth; Hanauer, Stephen B.; McDonald, John W.D. // New England Journal of Medicine;06/01/2000, Vol. 342 Issue 22, p1627 

    Background: Patients with Crohn's disease often have relapses. Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known. Methods: We conducted a double-blind,...

  • Altheus Targets Bowel Diseases With Combination Approach. Young, Donna // BioWorld Today;12/17/2007, Vol. 18 Issue 243, p1 

    The article deals with the effort of Altheus Therapeutics Inc. to develop a combination approach to treating inflammatory bowel disease (IBD). There are two chronic diseases that cause intestinal inflammation. The incidence of IBD in the U.S. and Europe is cited. According to Chief Executive...

  • Manchester University heads £10m EU-funded research network into inflammatory bowel disease.  // Gastrointestinal Nursing;Apr2013, Vol. 11 Issue 3, p6 

    The article reports that the University of Manchester is leading a 10 million Sterling Pound, 5-year research network to identify better treatments for inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC).

  • Le malattie infiammatorie croniche intestinali in età pediatrica. Pelosi, Paola; Cianchi, Ilaria; Paolacci, Giulia; Gissi, Anna; Paci, Monica; Naldini, Sara; Lionetti, Paolo // Children's Nurses: Italian Journal of Pediatric Nursing Science ;inverno2012/2013, Vol. 4 Issue 4, p122 

    Chronic inflammatory bowel diseases include two important conditions: Crohn disease and Ulcerative Colitis. Although they were considered rare among children in the past, these diseases have seen in the last decades a progressive increase in their incidence also in developing ages, and now they...

  • Pyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases With Good Response to Infliximab. Carrasco Cubero, Carmen; Ruiz Tudela, M. Mar; Salaberri Maestrojuan, José Javier; Pérez Venegas, José Javier // Reumatologia Clinica;mar/abr2012, Vol. 8 Issue 2, p90 

    Among the extraintestinal manifestations of inflammatory bowel disease (IBD), pyoderma gangrenosum (PG) often poses a therapeutic challenge. We describe two cases of PG associated with inflammatory bowel disease, who responded to treatment with Infliximab.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics